vTv Therapeutics Inc.

NASDAQ
VTVT
paper.types.company
Rentabilité sur six mois: +7.32%
Rendement en dividendes: 0%
Secteur: Healthcare

16.65 $

-1.12 $ -6.28%
12.93 $
24.36 $

paper.min_max_per_year

Calendrier des promotions vTv Therapeutics Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

plus de détails
It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2015-07-30
ISIN
US9183851057
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 78.36 1
P/BV 5.57 2
P/E 0 0
Efficacité
Nom Signification Grade
ROA -74.92 0
ROE 295.84 10
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0075 10
Debt/Ratio 0.0044 10
Debt/Equity 1.68 7
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -84.11 0
Rentabilité Ebitda, % 86.08 9
Rentabilité EPS, % 1607.99 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 17.76 $ 0 $ 0 $ -6.28 % 0 % 0 %
common.calendar.number_days.7d 19.99 $ 0 $ 0 $ -16.73 % 0 % 0 %
common.calendar.number_days.30d 23.17 $ 16.65 $ 21.25 $ -28.16 % 0 % 0 %
common.calendar.number_days.90d 18.64 $ 15.35 $ 23.17 $ -10.7 % 0 % 0 %
common.calendar.number_days.180d 15.51 $ 13.2 $ 23.17 $ 7.32 % 0 % 0 %
common.calendar.number_days.1y 24.66 $ 12.93 $ 24.36 $ -32.5 % 0 % 0 %
common.calendar.number_days.3y 0.5 $ 0.35 $ 593.6 $ 3229 % 0 % 0 %
common.calendar.number_days.5y 2.04 $ 0.35 $ 593.6 $ 715.93 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.35 $ 593.6 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 15.03 $ 13.34 $ 23.17 $ 10.75 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Paul J. Sekhri M.Sc. CEO, President & Chairman of the Board 650.91k 1958 (67 années)
Mr. Steven Tuch M.B.A. Executive VP & CFO 465.25k 1969 (56 années)
Mr. Richard S. Nelson Executive VP of Corporate Development & Director 201.08k 1970 (55 années)
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer & Executive VP N/A
Ms. Elizabeth M. Keiley Executive VP & General Counsel N/A 1966 (59 années)
Dr. Thomas Strack M.D., Ph.D. Chief Medical Officer N/A

Informations sur l'entreprise

Adresse: United States, High Point. NC, 3980 Premier Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://vtvtherapeutics.com